The U.S. Food and Drug Administration has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active nonradiographic axial ...
After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another powerhouse product—AbbVie’s Skyrizi—in psoriatic arthritis (PsA). A phase 3b ...
Jeffrey Stark, MD, vice president and head of medical immunology at UCB, analyzes the Bimzelx Navigate program, a comprehensive support system developed to empower patients prescribed bimekizumab-bkzx ...
BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate-to-severe plaque psoriasis Approval is supported by three Phase 3 ...
With three new indications, BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four chronic immune-mediated inflammatory diseases ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Two months after UCB revealed the success of Bimzelx in a head-to-head trial against AbbVie’s Skyrizi in patients with psoriatic arthritis (PsA), the Belgian drugmaker has unveiled the detailed ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Following an examination of clinical evidence and stakeholder input, Canada's Drug Agency (CDA-AMC) has recommended BIMZELX® (bimekizumab injection) for reimbursement with conditions for patients with ...
Please provide your email address to receive an email when new articles are posted on . Over 86% of patients maintained at least a 75% improvement in their diseases over the span of 2 years. The ...
Belgian biopharma company UCB (UCBJY) announced on Wednesday that its arthritis therapy Bimzelx outperformed AbbVie’s (ABBV) immunology therapy Skyrizi in a head-to-head trial for psoriatic arthritis, ...
BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: 49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results